1上海中医药大学研究生院，上海 201203；2上海健康医学院附属周浦医院内分泌-风湿科，上海 201318；3上海中医药大学，上海 201203
网络出版日期: 2025-08-16
基金资助
国家自然科学基金（81873636）；上海市医学重点专科项目资助（ZK2019C09）；浦东新区第二轮医学学科建设项目—临床特色学科（PWYts2021-09）；上海健康医学院甲状腺病临床研究中心（20MC20200002）
Research progress of targeted immunotherapy and immunoprophylaxis of type 1 diabetes mellitus
1Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; 2Depertment of Endocrinology ＆ Rheumatology, Shanghai University of Medicine ＆ Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China; 3Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Online published: 2025-08-16
Supported by
National Natural Science Foundation of China (81873636); Shanghai Medical Key Specialist Department Project (ZK2019C09); The Second Round of Medical Discipline Construction Project in Pudong New Area - Clinical Characteristic Discipline (PWYts2021-09); Clinical Research Center for Thyroid Diseases of Shanghai University of Medicine & Health Sciences (20MC20200002)
1型糖尿病是一种淋巴细胞介导胰岛β细胞发生进展性破坏导致的自身免疫病，近年来发病率迅速增长，患者以儿童、青少年为主。目前，以T淋巴细胞、B淋巴细胞、细胞因子为目标的靶向免疫治疗1型糖尿病已获得长足进展，此文针对不同靶点的各种药物对1型糖尿病的临床前期、临床研究疗效以及免疫预防方案进行综述。
关键词：
糖尿病，1型；靶向；免疫治疗；免疫预防
吴宇清 , 江妍斐 , 张进安 . 靶向免疫治疗和预防1型糖尿病的研究进展[J]. 国际生物制品学杂志, 2022 , 45(5) : 266 -271 . DOI: 10.3760/cma.j.cn311962-20220112-00006
Type 1 diabetes mellitus（T1DM） is an autoimmune disease characterized by lymphocyte-mediated progressive destruction of pancreatic β cells. T1DM mainly affects children and young adults, and its incidence has increased rapidly in recent years. At present, the immunotherapy targeting T-lymphocytes, B-lymphocytes and cytokines has made great progress in T1DM treatment. This article reviews the preclinical, clinical efficacies and immunoprophylaxis effects of different targeted drugs for T1DM.
/
| 〈 |
|
〉 |
沪公网安备 31010502000696号 沪ICP备05031153号-3